Monsieur Guillaume BERTON / Doctorant

Compétences

Formation GIRCI-MED, 24/06/2025 : écrire un article scientifique Posters en congrès internationaux : EHA 2023 : REAL: A RETROSPECTIVE STUDY OF THE CLINICO-BIOLOGICAL FEATURES OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES PATIENTS INCLUDED IN AN EARLY PHASE TRIAL AT A COMPREHENSIVE CANCER CENTER. ASH 2023 : Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients ASH2024 : Venetoclax-based therapy versus intensive chemotherapy followed by allogeneic-stem cell transplantation for high-risk elderly Acute Myeloid Leukemia SFGM-TC : 2024 : ÉTABLISSEMENT D'UN SCORE IMMUNOLOGIQUE PRÉDICTIF D'AGVHD APRÈS ALLOGREFFE HAPLO-IDENTIQUE AVEC PT-CY EHA 2025 : - PROGNOSTIC IMPACT OF BCOR/BCORL1 MUTATIONS IN ND-AML PATIENTS TREATED WITH VEN-HMA. Publications : - PROGNOSTIC IMPACT OF BCOR/BCORL1 MUTATIONS IN ND-AML PATIENTS TREATED WITH VEN-HMA. Author(s): Guillaume BERTON, Rebecca Bystrom, Shai Shimony, Jan Bewersdorf, Rory M. Shallis, Amer M. Zeidan, Aaron Goldberg, Andrius Žučenka, Maximillian Stahl, Sylvain Garciaz. (Abstract release date: 05/14/25) EHA Library. - Outcomes of Elderly Patients Admitted to the Intensive Care Unit for Newly Diagnosed Acute Myeloid Leukemia. G.Berton, MA.Hospital, S.Garciaz, et al. Eur J Haematol. 2025 Apr;114(4):679-689. - Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High-Risk MDS Treated With Nucleoside Analogs. E Collomb, L Bourguignon, A Tichadou, P Roche, G Berton, J Ciccolini, et al. Hematological oncology 43 (2), e70057 - Venetoclax-based therapy versus intensive chemotherapy followed by allogeneic-stem cell transplantation for high-risk elderly Acute Myeloid Leukemia. A Iat, JP Bewersdorf, J Gilhodes, Y Liu, RM Shallis, L Boussi, A Zucenka, et al. Blood 144, 1508 - Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, et al. Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1 ‐ or IDH2 ‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study. Am J Hematol. août 2024;99(8):1640‑3. - Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, et al. Intensive Induction Chemotherapy versus Hypomethylating Agents in Combination with Venetoclax in NPM1-mutant AML. Blood Adv. 28 juin 2024;blood advances.2024012858. - Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia . G Berton, B Sedaki, E Collomb, S Benachour, M Loschi, B Mohty, et al. Leukemia Research 141, 107500 - Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available. Garciaz S, Berton G, Hospital MA, Guille A, Adélaïde J, Saillard C, et al. Leuk Lymphoma. 15 avr 2024;65(5):700‑3. - Berton G, Sedaki B, Collomb E, Benachour S, Loschi M, Mohty B, et al. Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients. Blood. 28 nov 2023;142(Supplement 1):2848‑2848. - Berton G, Vicier C, Hospital MA, Saillard C, Hicheri Y, Maisano V, et al. PB1844: REAL: A RETROSPECTIVE STUDY OF THE CLINICO-BIOLOGICAL FEATURES OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES PATIENTS INCLUDED IN AN EARLY PHASE TRIAL AT A COMPREHENSIVE CANCER CENTER. HemaSphere. 8 août 2023;7(S3):e4520163 - Berton G, Arcani R, Tichadou A, Farnault L, Roche P, Colle J, et al. Therapy-related myeloid neoplasms after 177Lu-DOTATATE therapy for metastatic neuroendocrine neoplasia: CPX-351 consolidated by allogeneic stem cells transplantation as applicable therapeutic strategy. Leuk Lymphoma. 7 juin 2023;64(7):1355‑7

Techniques maîtrisées

Diplome d'études spécialisées en hématologie Expertise en leucémie aiguë myéloïde et en allogreffe de cellules souches hématopoïétiques